S. Lehnert, Yongbiao Li, E. Bump, Bill Riddoch, A. Chenite, M. Shive
{"title":"125I-Iododeoxyuridine for the Treatment of a Brain Tumor Model:Selection of Conditions for Optimal Effectiveness","authors":"S. Lehnert, Yongbiao Li, E. Bump, Bill Riddoch, A. Chenite, M. Shive","doi":"10.2174/1876388X01103010019","DOIUrl":null,"url":null,"abstract":"The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor. Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX. Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion: Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.","PeriodicalId":88754,"journal":{"name":"The open nuclear medicine journal","volume":"3 1","pages":"19-24"},"PeriodicalIF":0.0000,"publicationDate":"2011-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The open nuclear medicine journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1876388X01103010019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor. Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX. Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion: Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
